News

A new study found that the time it takes to diagnose alpha-gal syndrome has improved from 5.3 years to 28 days since 2011, but disparities remain based on education level.

Veeral Sheth, MD, is joined by the CEO of Neurotech to discuss the historic approval of revakinagene taroretcel (ENCELTO) for macular telangiectasia type 2.

Repka describes the complications of the US healthcare system and how to advance interactions in advocacy efforts.

Goel explains the importance of second-line therapies and describes the role PPARs play in PBC treatment, including 2 newly approved therapies.

Repka dives into the role of advocacy in shaping ophthalmologic policies and ensuring equitable patient care.

Lammert describes the clinical impact of having 2 new second-line PBC therapies, challenges to their uptake, and areas where more research is needed.

These data highlight the long-term maintenance of bimekizumab responses among individuals with psoriasis, looking at bio-naïve and bio-switched patients.

A study found that genetics and environment both influence allergy risk, but environmental factors play a stronger role in the progression of allergic disease.

An audio recap of the top 5 stories in healthcare news from the week of 03/16-03/23.

This interview with Ian Myles, MD, MPH, highlights his team’s recent findings on identifying dermatitis related to topical steroid withdrawal (TSW) versus atopic dermatitis.

Patients with hereditary angioedema report greater rates of autoimmune diseases, allergies, and asthma than the general population, highlighting key comorbidities.

Our top 5 headlines featured new migraine guidelines, the benefit of automated insulin delivery for type 2 diabetes, and 3 key FDA decisions.

A new cross-sectional study found that the odds of having bronchodilator responsiveness declined by 8% per hour during the working day.

Bhatt previews 3 late-breaking clinical trials being presented at this year's American College of Cardiology Annual Scientific Sessions.

A trio of nephrology experts discuss the significance of iptacopan’s FDA approval as the first treatment for C3G.

These data highlight differences and similarities among dermatologists globally in their decisions related to the treatment of mild-to-moderate atopic dermatitis.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key allergy updates from the 2025 American Academy of Allergy, Asthma, and Immunology (AAAAI) annual meeting.

By year 5, COPD exacerbations occurred in 81.3% of the PPV23 group and 23.6% of the PCV13 group.

Lammert discusses the shifting landscape of treatment response metrics and the latest advancements in second-line therapy for PBC.

Baricitinib treatment was safe among patients with alopecia areata over 48 weeks in a real-world treatment setting.

Martinez explains the pathophysiology and clinical presentation of pruritus in children with cholestatic liver disease as well as treatment options.

Examining recent developments in ASUC management, including predictive markers for colectomy, new treatment approaches, and ongoing challenges.

The approval expands the indication for vutrisiran, which becomes the first therapeutic approved by the FDA for the treatment of ATTR-CM.

The March 2025 approval for iptacopan marks the first for C3 glomerulopathy and is based on the APPEAR-C3G trial.

The approval for moderately to severely active Crohn disease marks the fourth indication for Johnson and Johnson's IL-23 inhibitor.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode highlights 5 key dermatology updates from the 2025 American Academy of Dermatology Annual Meeting in Orlando.

A new systematic review finds IV iron effective for iron non-responders but calls for further studies on the causes of oral iron failure.

Climate change worsens allergies by lengthening pollen seasons, increasing air pollution, and driving new food allergies. Experts offer strategies for clinicians.